Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NH3MPIdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWCwMVAvPSEQvF2= MkO1NlQhcA>? Mne5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NXnSR2pKOjV4NkO3Olk>
HepG2-HBV1.1 MUPBdI9xfG:|aYOgRZN{[Xl? M2DVflAuOC53IN88US=> M2jxR|I1KGh? NUjtdnMxcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M2rNfVI2PjZ|N{[5
HepG2.2.15 MnjCSpVv[3Srb36gRZN{[Xl? NUXRelA4OC5zIN88US=> NVTSUZdHOjRiaB?= M13rUJBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NHP1VFEzPTZ4M{e2PS=>
HepG2-HBV1.1 Mm\4SpVv[3Srb36gRZN{[Xl? MX2wMlEh|ryP MoCwNlQhcA>? NUj3eGZjeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v MlqyNlU3PjN5Nkm=
HepG2-HBV1.1 M13hUGZ2dmO2aX;uJGF{e2G7 M33mNVAvOSEQvF2= MnHIOFghcA>? NFzQRYdxem:vb4Tld{Bk\WyuIHX4Z5JmfGmxbjDv[kBp\XCjdHn0bZMhSiC4aYL1d{BvfWOuZX;jZZB{cWS|IHnud5Rm[WRib3[gbIVx[XSrdHnzJGIhfmm{dYOgSIFv\SCyYYL0bYNt\XN? M13ncFI2PjZ|N{[5
HepG2-HBV1.1 NWf0[lB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2NE4yKM7:TR?= NIfmZ2oyNTViZB?= NGnQZ5RqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 M{HZWFI2PjZ|N{[5
HepG2-HBV1.1 NUXMdG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD1NE4yKM7:TR?= M2DiWVEuPSCm NITD[FlqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NWXNdWp1OjV4NkO3Olk>
HepG2-HBV1.1 NHLi[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POPFAvOSEQvF2= MkD2NVIuPzJiaB?= MXTpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= NHP4N2wzPTZ4M{e2PS=>
HepG2-HBV1.1 M3zubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOwMlEh|ryP MnrwNVIuPzJiaB?= MlfFbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl MmrCNlU3PjN5Nkm=
Raji NUX4epdyTnWwY4Tpc44hSXO|YYm= NWPEZ|hGOC53wrFOwG0> NGm4TIc4OiCq MYDhZo9tcXOqZYOgZZV1d3CqYXf5xsA> NXjZRnVbOjV2NE[zO|c>
SK-MEL-28  NVXqOGM6TnWwY4Tpc44hSXO|YYm= NYPWWndZOzBibl2= NHjrNFk3KGh? M3HPXYlv\HWlZYOgS|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2 M4[1cFI2OzF|MEGw
H157 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vifGlEPTB;MT6wN{DDuSByLkC0JI1qfTKP MofLNlUzPTd7MUG=
Jurkat NHj4XZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xMVMhdk1? Moj5OFjDqGh? M1TmdGROW09? M{joOoRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NHzVc2czPTF3NkG0Oi=>
CEM NHXsOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PvPFEuOyCwTR?= M2rnVFQ5yqCq M4myW2ROW09? NGKwN2tl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 M4nofFI2OTV4MUS2
P12 NGrWUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zvTFEuOyCwTR?= MYC0POKhcA>? M1nKZWROW09? NWnyNJZ2\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NXzuXYxbOjVzNU[xOFY>
KB NF\6cndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTI[3l4UUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> NXrtbpdUOjVyNUi1NlY>
KBv200 (ABCB1) NFL3bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= MkPGNlUxPTh3Mk[=
SUDHL6  Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHZNgKBkc7:TR?= MYO0PE84OiCq M3TNRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NXjCW3lMOjR7NkG2NFQ>
SUDHL6  MXzGeY5kfGmxbjDBd5NigQ>? MnrINgKBkc7:TR?= NF;Lflc4OiCq M3TJOYlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? NFjxdIMzPDl4MU[wOC=>
HCT-116 M3HFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfMVFFIUTVyPUWgcm0> MV6yOFkzPzh3Nx?=
SKNBe2C NEPRdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjIU4dKSzVyPUOyMljDuTRwMDDuUS=> MV6yOFkzOTl{MB?=
IGNR91 NHKyfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jsRmlEPTB;MkSuN:KyOS55IH7N M4jtR|I1QTJzOUKw
SKNAS Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DMeWlEPTB;MT61xtExNjJibl2= MojTNlQ6OjF7MkC=
LAN1 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqwNlhKSzVyPUKuN:KyOC5{IH7N NGrwdI4zPDl{MUmyNC=>
SHSY5Y M4m3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj2ZlNKSzVyPUiuNuKyOC54IH7N NEfaOoIzPDl{MUmyNC=>
A549-WT NHv6XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fkSmlEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?= MoHWNlQ5PTh6Mke=
A549-R NG\FXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? NIPMd4ozPDh3OEiyOy=>
MCF-7-WT NEnvUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr3fnc2UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N Mn:1NlQ5PTh6Mke=
MCF-7-R MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTVwNUO5JOKyKDBwMUS0JEBvVQ>? NFX6doUzPDh3OEiyOy=>
A549-R MV;DfZRwfG:6aXPpeJkhSXO|YYm= NGLoPIFKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?= NIDtTJYzPDh3OEiyOy=>
MCF-7-R M2\zNGN6fG:2b4jpZ4l1gSCDc4PhfS=> M1;rd2lEPTB;NT61N|khyrFiMD6xOFQhdk1? NVfNXGdPOjR6NUi4Nlc>
SW620 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLEXlBKSzVyPUeuPFAhyrFiMD6wPEBvVQ>? M1vXdlI1PzJ4N{O5
SW620/AD300 NIXoXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD17MEmuOlAhyrFiOD65NUBvVQ>? M2TVW|I1PzJ4N{O5
HEK293/pcDNA3.1 NYXZRVBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn4SpJKSzVyPUGuOFUhyrFiMD6yNEBvVQ>? MnfRNlQ4OjZ5M{m=
HEK293/ABCC1 NXTlNY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrVelJKSzVyPUG5MlI6KMLzIEKuNFghdk1? M{fqT|I1PzJ4N{O5
TCC NVnoS|JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2wNlQhcA>? NHzCOFlKSzVyPUewJI5O NWHGZpNoOjR5MU[5OFQ>
TCC NXHCVVd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3tV4w1QCCq MmHSTWM2OD13MDDuUS=> NHXzPVYzPDdzNkm0OC=>
HepG2/ADM NUHqW2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDJTWM2OD1{Lke4OlPDuTBwMkO3NUDPxE1? M1nsWFI1PzB2NUW2
HepG2 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLMTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? NGi0XIozPDdyNEW1Oi=>
MCF-7/ADR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwNEiyOuKyOC5{MEewJO69VQ>? NX31OJRQOjR5MES1OVY>
MCF-7 NWfu[WFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX2RXBKSzVyPUCuNFE2QcLzMD6wNFYzKM7:TR?= NVz4SHVYOjR5MES1OVY>
A-172  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1THUVAvOcLizszN MnTuNlQwPzJiaB?= MmHGbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NUfmOGIzOjR3M{CyN|U>
U-251MG NIfwTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zlV|AvOcLizszN NWSzWnV4OjRxN{KgbC=> NV7Le211cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NYnZfpZLOjR3M{CyN|U>
DLD-1 M1TtSGZ2dmO2aX;uJGF{e2G7 MlH1NVAxKG6P M13kS|Q5KGh? M1XRVpBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? Mn3nNlQ1ODN2NUO=
CCD18Co NVmybGZ[TnWwY4Tpc44hSXO|YYm= MnjBNVAxKG6P NUjGR2VbPDhiaB?= M4rtSpBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? Mm\vNlQ1ODN2NUO=
DLD-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCwMVExODBibl2= M1j1NVQ5KGh? MlzkbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4K2PFI1PDB|NEWz
CCD18Co NInwOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4UIdZOC1zMECwJI5O M4DUblQ5KGh? NYHzZol[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MnvDNlQ1ODN2NUO=
HepG2 NYrrcHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPG[5IzPCCq NXvKXGN3UUN3ME21Nk426oDLzszN NXnRUYdZOjR|NEG2PFg>
HEK293/pcDNA3.1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP3fIZWUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?= MXOyOFI5PDd6Mx?=
HEK293/MRP1 NVHIRnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHqd|lwUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= MmflNlQzQDR5OEO=
Ramos M1fOW2Fxd3C2b4Ppd{BCe3OjeR?= NVGwcVcyOuLCid88US=> M13GSVQ5KGh? MkLKbY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{ NVPTZoxROjR{NU[0PVE>
NCI-H1299/pcDNA3 Mn;wR4VtdCCYaXHibYxqfHliQYPzZZk> M{\zeFAuOjBibl2= NYnFdXJVQTZiaB?= MX7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M13BTVI1OTd5MEGy
H1299/ICAM-3 MmXPR4VtdCCYaXHibYxqfHliQYPzZZk> M2HsXFAuOjBibl2= MmLxPVYhcA>? MULpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWf1eYNFOjRzN{ewNVI>
NCI-H1299/pcDNA3 M4[2fWZ2dmO2aX;uJGF{e2G7 NFzufmwyNzVxMUCvNlDDqG6P NF\2cZc6PiCq NUnGSGV5cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M{fwWFI1OTd5MEGy
H1299/ICAM-3 MlP5SpVv[3Srb36gRZN{[Xl? Mn23NU82NzFyL{KwxsBvVQ>? NFfwW206PiCq MnThbY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> MUKyOFE4PzBzMh?=
W1 NI\pbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L4OmlEPTB;MD6wNFMzKM7:TR?= NV[4c|VvOjRzNECxO|Y>
W1VR NY\rSmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofETWM2OD1yLkC1OkDPxE1? M3XPdFI1OTRyMUe2
K562 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDFTFFKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2= M2jxSVI1OTN3OUO3
K562/ADR NFXERpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGbGlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP MX6yOFE{PTl|Nx?=
K562 MnXERZBweHSxc3nzJGF{e2G7 NXLXeFJxOC5|IN88US=> MlH6NlQhcA>? NYXKUFZYcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M1z6O|I1OTN3OUO3
K562/ADR MnHIRZBweHSxc3nzJGF{e2G7 MVSzJO69VQ>? Mn\nNlQhcA>? M1TnWIlv\HWlZYOgZZBweHSxc3nz Ml\CNlQyOzV7M{e=
A549 NVm0XoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnmTWM2OD1yLkGwJOKyKDBwMEOg{txO MYGyN|k4OTB5NR?=
K562 MlPrR4VtdCCYaXHibYxqfHliQYPzZZk> M1r1e|MvPzYkgKO2NOKhdk1? NH\1Slg4OsLiaNMg NFPafYdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MVSyN|g4PzJ{Mx?=
lucena MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWX3R2pROy55NfMAl|YxyqCwTR?= NEXmV|U4OsLiaNMg MkfIco8h\W[oZXP0 NWDqe4Q{OjN6N{eyNlM>
FEPS M2D5[WNmdGxiVnnhZoltcXS7IFHzd4F6 NGDNcHQ{Njd34pETOlDDqG6P M17xZ|czyqCqwrC= MljIco8h\W[oZXP0 NHr4eYszOzh5N{KyNy=>
A2780 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX33U2JZUUN3ME2zMlUhdU1? NIDzTGIzOzh{OUKwNy=>
ACHN NULrVWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2ODxyLkGgcW0> NXTkb3dHOjN6MkmyNFM>
U-937 NH7xUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XKfmlEPTB:M{Sgcm0> NHXhS2ozOzh{OUKwNy=>
Jurkat MV\BdI9xfG:|aYOgRZN{[Xl? NWe1bm5qPcLizsznM41tyqB? MWKyOEBp MnS5bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M1fFcFI{QDFyNEC5
Jurkat Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DVPFXDqM7:Zz;tcOKh MYqyOEBp M1;IdIFzemW|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG|ZR?= NGWwbmozOzhzMESwPS=>
Hep-2 M2LzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTne5ZMUUN3ME2wMlA1yrFyLkCxJO69VQ>? NF;mSoIzOzd6MESyOC=>
Hep-2/v NYqz[|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnTTGtKSzVyPUGuPOKyOC5{MDFOwG0> M2rleVI{PzhyNEK0
SGC-7901 M{[ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xqc|AuOTBizsznM41t M2D5VFI1NzR6L{eyJIg> NI\yTXdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M4XwPFI{PzR|NUey
SGC-7901/VCR Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMVExKM7:Zz;tcC=> Mof3NlQwPDhxN{KgbC=> MkTHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MV6yN|c1OzV5Mh?=
SGC-7901 NHTKSIpCeG:ydH;zbZMhSXO|YYm= MVnpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MX[yN|c1OzV5Mh?=
SGC-7901/VCR MXPBdI9xfG:|aYOgRZN{[Xl? NGrSPWFqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NVzHXml{OjN5NEO1O|I>
KB-3-1 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNk[gxtEhOC5zNkKg{txO MlvuNlM3PzN2NEW=
KB-C2 NHnTOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNS2lEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= NWXtU281OjN4N{O0OFU>
KB-3-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfRZnJvUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= MlSyNlM3PzN2NEW=
KB-V1 M17Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG1TWM2OD1{MEiuPFUhyrFiMkCuOEDPxE1? MmDKNlM3PzN2NEW=
HEK293/pcDNA3.1 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ2LkGgxtEhOC5{MESg{txO NGfF[2ozOzZ5M{S0OS=>
HEK293/ABCB1 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL3fIZ{UUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> MX:yN|Y4OzR2NR?=
A549/EGFP  M4[4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzUlAvODFvMUCwNEDPxE1? NI\keo1KSzVyPUi2MlchyrFiMkmuNUDPxE1? MlTCNlM3OzR{OEK=
A549/Slug NYjoc|ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMlAyNTFyMECg{txO MnnNTWM2OD17LkegxtEhOy5zIN88US=> M4myclI{PjN2Mkiy
JFCR39  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexJOK2VQ>? NF7BfpkzPCCq M4rrOmROW09? NFPVUplu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| MXmyN|U6QDJ5Nh?=
A549 MnHhSpVv[3Srb36gRZN{[Xl? NV;QUGE1OTByIH7N MkHjNVYhcA>? NWjVUFBFTE2VTx?= NGHrS|ht\WGmczD0c{BiKGyxc4Ogc4YhdWmlcn;0eYJ2dGW| Mk\CNlM2QTh{N{[=
SGC7901 NYD3bVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwMkdihKnDueLCiUCuNVEh|rypL33s M{PNcVI{PTZ2NEiy
SGC7901/LV-NC M4\5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7oS|RXUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? MYmyN|U3PDR6Mh?=
SGC7901/LV-SGO1 NIe4TVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1b2lEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> NUTIc5RyOjN3NkS0PFI>
SGC7901/VCR NXjlVG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|U{RTJyLkWz5qCKyrIkgJmxMlk3KM7:Zz;tcC=> MnHYNlM2PjR2OEK=
SGC7901/VCR-NC NXXUe|dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0cIdKSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? MmfTNlM2PjR2OEK=
SGC7901/VCR-si-SGO1 NEfmTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s NInvTHczOzV4NES4Ni=>
SGC7901/ADR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT1boxKSzVyPUeuPFXjiIoEsfMAjVAvPjRizsznM41t MofCNlM2PjR2OEK=
SGC7901/ADR-NC NIjhVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThwOURihKnDueLCiUCuOlgh|rypL33s NXewT3N5OjN3NkS0PFI>
SGC7901/ADR-si-SGO1 NF[5[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HiXWlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> NVHTfoZkOjN3NkS0PFI>
SH-SY5Y  M2Oz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPTdpIxNjByMT2xNEDPxE1? NXOxb4FxOjRiaB?= NYrneGt2UUN3ME2wMlEyO8LzMD6wNVIh|ryP MViyN|EzQTB4NR?=
SH-SY5Y  Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETlZpgxNjByMT2xNEDPxE1? Mn;1OFghcA>? NULiR444UUN3ME2wMlA4QMLzMD6wNFkh|ryP MY[yN|EzQTB4NR?=
SH-SY5Y  NYLYd49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jB[lAvODBzLUGwJO69VQ>? M4XJUlczKGh? M2S0c2lEPTB;MD6wOVHDuTBwMEC4JO69VQ>? NIrpb40zOzF{OUC2OS=>
SH-SY5Y NIr5WIlCeG:ydH;zbZMhSXO|YYm= MmHvNE4yKM7:TR?= NWix[pduOC1{NDDo Ml7MbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= M2rVNlI{OTJ7ME[1
SH-SY5Y MmjyRZBweHSxc3nzJGF{e2G7 Mn\HNE4yKM7:TR?= M1Tyd|AuOjRiaB?= MonKbY5lfWOnczDtbZRwfGmlIHHydoV{fMLi M3LqWFI{OTJ7ME[1

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol <1 mg/mL
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023358 Not yet recruiting Peripheral T Cell Lymphoma Nanfang Hospital of Southern Medical University February 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03003520 Recruiting Lymphoma, Large B-Cell, Diffuse Celgene February 2017 Phase 2
NCT03018626 Not yet recruiting Lymphoma, Large B-Cell, Diffuse Nanfang Hospital of Southern Medical University February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID